Eric Haura MD

Oncology•Tampa, FL

Associate Professor, Oncologic Sciences, USF-Morsani

Request Appointment

12902 Usf Magnolia DrTampa, FL 33612
Book by Phone+1(267) 314-8048
Fax+1 813-745-6817

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 1997 - 2000
Johns Hopkins UniversityResidency, Internal Medicine, 1994 - 1997
Duke University School of MedicineClass of 1994

Certifications & Licensure

FL State Medical License 2000 - 2027
NC State Medical License 1999 - 2001
American Board of Internal Medicine Medical Oncology

Clinical Trials

Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates Start of enrollment: 2004 Oct 01
Terminated
Not Applicable
Phase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC) Start of enrollment: 2007 Mar 01
Completed
Phase 1
Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation Start of enrollment: 2009 Mar 01
Terminated
Phase 2
Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer Start of enrollment: 2012 Mar 26
Completed
Phase 1, Phase 2
Smoking Relapse-Prevention Intervention for Cancer Patients Start of enrollment: 2012 Jan 04
Completed
Not Applicable
A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation Start of enrollment: 2013 Dec 30
Completed
Phase 1
A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants Start of enrollment: 2013 Aug 01
Completed
Phase 2
Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC) Start of enrollment: 2013 Dec 31
Completed
Phase 1
Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC Start of enrollment: 2019 Feb 01
ACTIVE_NOT_RECRUITING
PHASE1
Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC Start of enrollment: 2020 Nov 23
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

An examination of factors associated with disparities in clinical trial eligibility guided by the Socioecological Model.
Yayi Zhao, Rossybelle P Amorrortu, J Kevin Hicks, Melany A Garcia, Eric B Haura
Cancer. 2025-07-01
1 citations
Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study.
Matthew G Krebs, Byoung Chul Cho, Sandrine Hiret, Ji-Youn Han, Ki Hyeong Lee
Journal of Thoracic Oncology. 2025-05-16
Impaired T cell and neoantigen retention in time-serial analysis of metastatic non-small cell lung cancer in patients unresponsive to TIL cell therapy.
Chao Wang, Xiaoqing Yu, Jamie K Teer, Jiqiang Yao, Dongliang Du
Nature Cancer. 2025-05-01

Abstracts/Posters

Bromodomain and Extra Terminal Domain (BET) Inhibitors Sensitize Chronic Myelomonocytic Leukemia (CMML) to PIM Inhibition Via Downregulation of Mir-33a
Eric B. Haura, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC).
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Protein Interaction Assay May Identify Best NSCLC Candidates for KRAS G12C InhibitorsFebruary 5th, 2025
Moffitt Study Finds Key Biomarker to Predict KRASG12C Inhibitor Effectiveness in Lung CancerJanuary 31st, 2025
Moffitt Research Identifies Crucial Biomarker for Predicting Effectiveness of KRASG12C Inhibitors in Lung Cancer TreatmentJanuary 31st, 2025
Join now to see all

Insurance Accepted

Aetna Choice POS II
Aetna HMO
AvMed Health Open Access
BCBS Blue Card PPO
BCBS California PPO
BCBS Florida BlueCare HMO
BCBS Florida NetworkBlue
BCBS Florida Preferred Patient Care PPO
Blue Shield California PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Cofinity PPO
Coventry Florida - Employer Group PPO
First Health PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PHCS PPO - Kaiser
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment